Glycoengineering of therapeutic antibodies enhances monocyte/macrophage- mediated phagocytosis and cytotoxicity

Journal of Immunology

Volumn 192, Issue 5, 2014, Pages 2252-2260

  Herter, Sylvia ^a   Birk, Martina C ^a   Klein, Christian ^a   Gerdes, Christian ^a   Umana, Pablo ^a   Bacac, Marina ^a  

^a Discovery Oncology Pharma Research and Early Development (pRED) Roche Glycart AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CD16 ANTIGEN; CD32 ANTIGEN; CD64 ANTIGEN; CELL ANTIBODY; FC RECEPTOR; FCGAMMARIIIA; IMMUNOGLOBULIN G; NITRIC OXIDE; UNCLASSIFIED DRUG;

ANTIBODY ENGINEERING; ARTICLE; ATTENUATION; BINDING AFFINITY; CELL ISOLATION; CELL MEDIATED CYTOTOXICITY; CELL SUBPOPULATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; MACROPHAGE; MACROPHAGE ACTIVATION; MONOCYTE; PHAGOCYTOSIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; WILD TYPE;

ANIMALS; ANTIBODIES, MONOCLONAL; HUMANS; IMMUNITY, CELLULAR; IMMUNOGLOBULIN G; KILLER CELLS, NATURAL; MACROPHAGES; MICE; MONOCYTES; PROTEIN ENGINEERING; RECEPTORS, IGG;

EID: 84896499999     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1301249     Document Type: Article

References (45)

1. Shuptrine, C. W., R. Surana, and L. M. Weiner. 2012. Monoclonal antibodies for the treatment of cancer. Semin. Cancer Biol. 22: 3-13.
2. Weiner, L. M., J. C. Murray, and C. W. Shuptrine. 2012. Antibody-based immunotherapy of cancer. Cell 148: 1081-1084.
3. Weiner, L. M., R. Surana, and S. Wang. 2010. Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat. Rev. Immunol. 10: 317-327.
4. Reichert, J. M. 2011. Antibody-based therapeutics to watch in 2011. MAbs 3: 76-99.
5. Herter, S., F. Herting, O. Mundigl, I. Waldhauer, T. Weinzierl, T. Fauti, G. Muth, D. Ziegler-Landesberger, E. Van Puijenbroek, S. Lang, et al. 2013. Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models. Mol. Cancer Ther. 12: 2031-2042.
6. Mössner, E., P. Brünker, S. Moser, U. Püntener, C. Schmidt, S. Herter, R. Grau, C. Gerdes, A. Nopora, E. Van Puijenbroek, et al. 2010. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood 115: 4393-4402.
7. Adams, G. P., and L. M. Weiner. 2005. Monoclonal antibody therapy of cancer. Nat. Biotechnol. 23: 1147-1157.
8. Jaglowski, S. M., L. Alinari, R. Lapalombella, N. Muthusamy, and J. C. Byrd. 2010. The clinical application of monoclonal antibodies in chronic lymphocytic leukemia. Blood 116: 3705-3714.
9. Nimmerjahn, F., and J. V. Ravetch. 2005. Divergent immunoglobulin g subclass activity through selective Fc receptor binding. Science 310: 1510-1512.
10. Nimmerjahn, F., and J. V. Ravetch. 2006. Fcgamma receptors: old friends and new family members. Immunity 24: 19-28.
11. Sburlati, A. R., P. Umana, E. G. Prati, and J. E. Bailey. 1998. Synthesis of bisected glycoforms of recombinant IFN-beta by overexpression of beta-1,4-Nacetylglucosaminyltransferase III in Chinese hamster ovary cells. Biotechnol. Prog. 14: 189-192.
12. Shields, R. L., J. Lai, R. Keck, L. Y. O'Connell, K. Hong, Y. G. Meng, S. H. Weikert, and L. G. Presta. 2002. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibodydependent cellular toxicity. J. Biol. Chem. 277: 26733-26740.
13. Shinkawa, T., K. Nakamura, N. Yamane, E. Shoji-Hosaka, Y. Kanda, M. Sakurada, K. Uchida, H. Anazawa, M. Satoh, M. Yamasaki, et al. 2003. The absence of fucose but not the presence of galactose or bisecting N-Acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibodydependent cellular cytotoxicity. J. Biol. Chem. 278: 3466-3473.
14. Ferrara, C., S. Grau, C. Jäger, P. Sondermann, P. Brünker, I. Waldhauer, M. Hennig, A. Ruf, A. C. Rufer, M. Stihle, et al. 2011. Unique carbohydratecarbohydrate interactions are required for high affinity binding between FcgammaRIII and antibodies lacking core fucose. Proc. Natl. Acad. Sci. USA 108: 12669-12674.
15. Ferrara, C., P. Brünker, T. Suter, S. Moser, U. Püntener, and P. Umana. 2006. Modulation of therapeutic antibody effector functions by glycosylation engineering: influence of Golgi enzyme localization domain and co-expression of heterologous beta1, 4-N-Acetylglucosaminyltransferase III and Golgi alphamannosidase II. Biotechnol. Bioeng. 93: 851-861.
16. Ferrara, C., F. Stuart, P. Sondermann, P. Brünker, and P. Umana. 2006. The carbohydrate at FcgammaRIIIa Asn-162. An element required for high affinity binding to non-fucosylated IgG glycoforms. J. Biol. Chem. 281: 5032-5036.
17. Gerdes, C. A., V. G. Nicolini, S. Herter, E. Van Puijenbroek, S. Lang, M. Roemmele, E. Moessner, O. Freytag, T. Friess, C. H. Ries, B. Bossenmaier, H. J. Mueller, and P. Umana. 2013. GA201 (RG7160): a novel, humanized, glycoengineered anti-EGFR antibody with enhanced ADCC and superior in vivo efficacy compared with cetuximab. Clin. Canc. Res. 19: 1126-1138.
18. Salles, G., F. Morschhauser, T. Lamy, N. Milpied, C. Thieblemont, H. Tilly, G. Bieska, E. Asikanius, D. Carlile, J. Birkett, et al. 2012. Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients. Blood 119: 5126-5132.
19. Sehn, L. H., S. E. Assouline, D. A. Stewart, J. Mangel, R. D. Gascoyne, G. Fine, S. Frances-Lasserre, D. J. Carlile, and M. Crump. 2012. A phase 1 study of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed CD20-positive B-cell malignancies. Blood 119: 5118-5125.
20. Illidge, T. M. 2012. Obinutuzumab (GA101)-A different anti-CD20 antibody with great expectations. Expert Opin. Biol. Ther. 12: 543-545.
21. Ishii, T., T. Ishida, A. Utsunomiya, A. Inagaki, H. Yano, H. Komatsu, S. Iida, K. Imada, T. Uchiyama, S. Akinaga, K. Shitara, and R. Ueda. 2010. Defucosylated humanized anti-CCR4 monoclonal antibody KW-0761 as a novel immunotherapeutic agent for adult T-cell leukemia/lymphoma. Clin. Canc. Res. 16: 1520-1531.
22. Kubota, T., R. Niwa, M. Satoh, S. Akinaga, K. Shitara, and N. Hanai. 2009. Engineered therapeutic antibodies with improved effector functions. Cancer Sci. 100: 1566-1572.
23. Ashraf, S. Q., P. Umana, E. Mössner, T. Ntouroupi, P. Brünker, C. Schmidt, J. L. Wilding, N. J. Mortensen, and W. F. Bodmer. 2009. Humanised IgG1 antibody variants targeting membrane-bound carcinoembryonic antigen by antibody-dependent cellular cytotoxicity and phagocytosis. Br. J. Cancer 101: 1758-1768.
24. Gennari, R., S. Menard, F. Fagnoni, L. Ponchio, M. Scelsi, E. Tagliabue, F. Castiglioni, L. Villani, C. Magalotti, N. Gibelli, et al. 2004. Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2. Clin. Canc. Res. 10: 5650-5655.
25. Uchida, J., Y. Hamaguchi, J. A. Oliver, J. V. Ravetch, J. C. Poe, K. M. Haas, and T. F. Tedder. 2004. The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J. Exp. Med. 199: 1659-1669.
26. Minard-Colin, V., Y. Xiu, J. C. Poe, M. Horikawa, C. M. Magro, Y. Hamaguchi, K. M. Haas, and T. F. Tedder. 2008. Lymphoma depletion during CD20 immunotherapy in mice is mediated by macrophage FcgammaRI, FcgammaRIII, and FcgammaRIV. Blood 112: 1205-1213.
27. Tedder, T. F., A. Baras, and Y. Xiu. 2006. Fcgamma receptor-dependent effector mechanisms regulate CD19 and CD20 antibody immunotherapies for B lymphocyte malignancies and autoimmunity. Springer Semin. Immunopathol. 28: 351-364.
28. Gong, Q., Q. Ou, S. Ye, W. P. Lee, J. Cornelius, L. Diehl, W. Y. Lin, Z. Hu, Y. Lu, Y. Chen, et al. 2005. Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. J. Immunol. 174: 817-826.
29. Montalvao, F., Z. Garcia, S. Celli, B. Breart, J. Deguine, N. Van Rooijen, and P. Bousso. 2013. The mechanism of anti-CD20-mediated B cell depletion revealed by intravital imaging. J. Clin. Invest. 123: 5098-5103.
30. Golay, J., F. Da Roit, L. Bologna, C. Ferrara, J. H. Leusen, A. Rambaldi, C. Klein, and M. Introna. 2013. Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab. Blood 122: 3482-3491.
31. Luo, C., M. Chen, A. Madden, and H. Xu. 2012. Expression of complement components and regulators by different subtypes of bone marrow-derived macrophages. Inflammation 35: 1448-1461.
32. Galbán, S., Y. H. Jeon, B. M. Bowman, J. Stevenson, K. A. Sebolt, L. M. Sharkey, M. Lafferty, B. A. Hoff, B. L. Butler, S. S. Wigdal, et al. 2013. Imaging proteolytic activity in live cells and animal models. PLoS ONE 8: e66248.
33. Weber, T. G., T. Pöschinger, S. Galbán, A. Rehemtulla, and W. Scheuer. 2013. Noninvasive monitoring of pharmacodynamics and kinetics of a death receptor 5 antibody and its enhanced apoptosis induction in sequential application with doxorubicin. Neoplasia 15: 863-874.
34. Biswas, S. K., and A. Mantovani. 2010. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat. Immunol. 11: 889-896.
35. Mantovani, A., A. Sica, S. Sozzani, P. Allavena, A. Vecchi, and M. Locati. 2004. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 25: 677-686.
36. Kou, P. M., and J. E. Babensee. 2011. Macrophage and dendritic cell phenotypic diversity in the context of biomaterials. J. Biomed. Mater. Res. A. 96: 239-260.
37. Lolmede, K., L. Campana, M. Vezzoli, L. Bosurgi, R. Tonlorenzi, E. Clementi, M. E. Bianchi, G. Cossu, A. A. Manfredi, S. Brunelli, and P. Rovere-Querini. 2009. Inflammatory and alternatively activated human macrophages attract vessel-Associated stem cells, relying on separate HMGB1-And MMP-9-dependent pathways. J. Leukoc. Biol. 85: 779-787.
38. Cecchini, M. G., M. G. Dominguez, S. Mocci, A. Wetterwald, R. Felix, H. Fleisch, O. Chisholm, W. Hofstetter, J. W. Pollard, and E. R. Stanley. 1994. Role of colony stimulating factor-1 in the establishment and regulation of tissue macrophages during postnatal development of the mouse. Development 120: 1357-1372.
39. Kägi, D., B. Ledermann, K. Bürki, P. Seiler, B. Odermatt, K. J. Olsen, E. R. Podack, R. M. Zinkernagel, and H. Hengartner. 1994. Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice. Nature 369: 31-37.
40. Rafiq, S., J. P. Butchar, C. Cheney, X. Mo, R. Trotta, M. Caligiuri, D. Jarjoura, S. Tridandapani, N. Muthusamy, and J. C. Byrd. 2013. Comparative assessment of clinically utilized CD20-directed antibodies in chronic lymphocytic leukemia cells reveals divergent NK cell, monocyte, and macrophage properties. J. Immunol. 190: 2702-2711.
41. Patz, M., P. Isaeva, N. Forcob, B. Müller, L. P. Frenzel, C. M. Wendtner, C. Klein, P. Umana, M. Hallek, and G. Krause. 2011. Comparison of the in vitro effects of the anti-CD20 antibodies rituximab and GA101 on chronic lymphocytic leukaemia cells. Br. J. Haematol. 152: 295-306.
42. Laprevotte, E., G. Voisin, L. Ysebaert, C. Klein, C. Daugrois, G. Laurent, J. J. Fournie, and A. Quillet-Mary. 2013. Recombinant human IL-15 transpresentation by B leukemic cells from chronic lymphocytic leukemia induces autologous NK cell proliferation leading to improved anti-CD20 immunotherapy. J. Immunol. 191: 3634-3640.
43. Pander, J., M. Heusinkveld, T. Van der Straaten, E. S. Jordanova, R. Baak-Pablo, H. Gelderblom, H. Morreau, S. H. Van der Burg, H. J. Guchelaar, and T. Van Hall. 2011. Activation of tumor-promoting type 2 macrophages by EGFRtargeting antibody cetuximab. Clin. Can. Res. 17: 5668-5673.
44. Canioni, D., G. Salles, N. Mounier, N. Brousse, M. Keuppens, F. Morchhauser, T. Lamy, A. Sonet, M. C. Rousselet, C. Foussard, and L. Xerri. 2008. High numbers of tumor-Associated macrophages have an adverse prognostic value that can be circumvented by rituximab in patients with follicular lymphoma enrolled onto the GELA-GOELAMS FL-2000 trial. J. Clin. Oncol. 26: 440-446.
45. Taskinen, M., M. L. Karjalainen-Lindsberg, H. Nyman, L. M. Eerola, and S. Leppa. 2007. A high tumor-Associated macrophage content predicts favorable outcome in follicular lymphoma patients treated with rituximab and cyclophosphamide-doxorubicin-vincristine-prednisone. Clin. Cancer Res. 13: 5784-5789.